Proteomic profile in familial breast cancer patients

Clinical Biochemistry

Volumn 46, Issue 3, 2013, Pages 259-265

  Garrisi, V M ^a   Tommasi, S ^a   Facchiano, A ^b   Bongarzone, I ^c   De Bortoli, M ^c   Cremona, M ^c   Cafagna, V ^a   Abbate, I ^a   Tufaro, A ^a   Quaranta, M ^a   Paradiso, A ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b CNR   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Familial breast cancer; Proteome; SELDI ToF; Serum profiling

Indexed keywords

PROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; COMPUTER MODEL; CONTROLLED STUDY; DECISION TREE; FAMILIAL BREAST CANCER; FAMILIAL CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SPORADIC BREAST CANCER; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

BLOOD PROTEINS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; EARLY DETECTION OF CANCER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; PROSPECTIVE STUDIES; PROTEIN ARRAY ANALYSIS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84871961786     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.11.003     Document Type: Article

References (23)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics. Cancer J Clin 2010, 60:277-300.
2. Lalloo F., Evans D.G. Familial Breast Cancer. Clin Genet 2012, 82(2):105-114.
3. Krepischi A.C.V., Achatz M.I.W., Santos E.M.M., Costa S.S., Lisboa cG, Brentani H., et al. Germline DNA copy number variation in familial and early-onset breast cancer. Breast Cancer Res 2012, 14:R24.
4. Jiang X., Castelao J.E., Chavez-Uribe E., Rodriguez B.F., Munoz C.C., Redondo C.M., et al. Family history and breast cancer hormone receptor status in a Spanish cohort. PLoS One 2012, 7(1):e29459.
5. Engwegen J.Y., Gast M.C., Schellens J.H., Beijnen J.H. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci 2006, 27(5):251-259.
6. Lord S.J., Lei W., Craft P., Cawson J.N., Morris I., Walleser S., et al. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer 2007, 43:1905-1917.
7. Harry L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumour markers in breast cancer. J Clin Oncol 2007, 25(33).
8. Garrisi V.M., Abbate I., Quaranta M., Mangia A., Tommasi S., Paradiso A., et al. SELDI-TOF serum proteomics & breast cancer: which perspective?. Expert Rev Proteomics 2008, 5(6):779-785.
9. Garrisi V.M., Bongarzone I., Mangia A., Cremona M., De Bortoli M., Vaghi E., et al. Characterization of a serum protein pattern from NSCLC patients treated with Gefitinib. Clin Biochem 2011, 44(10-11):936-940.
10. Tommasi S., Pilato B., Pinto R., Monaco A., Bruno M., Campana M., et al. Molecular and in silico analysis of BRCA1 and BRCA2 variants. Mutat Res 2008 Sep 26, 644(1-2):64-70.
11. Gast M.C., van Gils C.H., Wessels L.F.A., Harris N., Bonfrer J.M.G., EJTh Rutgers, et al. Clin Chem Lab Med 2009, 47(6):694-705.
12. Li J., Zhang Z., Rosenzweig J., Young Y.W., Chan D.W., et al. Proteomics and Bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002, 48(8):1296-1304.
13. Li J., Orlandi R., White C.N., Rosenzweig J., Zhao J., Seregni E., et al. Indipendent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem 2005, 51:2229-2235.
14. Mathelin C., Cromer A., Wendling C., Tomasetto C., Rio M.C., et al. Serum biomarkers for detection of breast cancer: a prospective study. Breast Cancer Res Treat 2006, 96:83-90.
15. Vlahou A., Laronga C., Wilson L., Gregory B., Mc Gaugher D., Perry R., et al. A novel approach toward the development of rapid blood test for breast cancer. Clinical Breast Cancer 2003, 4(3):203-209.
16. Hu Y., Zhang S., Yu J., Liu J., Zheng S., et al. SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnoses of breast cancer. Breast 2005, 14(4):250-255.
17. Van Winden A.W.J., Gast M.C., Beijnen J.H., Rutgers E.J.Th., Grobbee D.E., Peeters P.H.M., et al. Validation of previously identified serum biomarkers for breast cancer with SELDI TOF MS: a case control study. BMC Med Genomics 2009, 2(4).
18. Becker S., Cazares L.H., Watson P., Lynch H., Semmes O.J., Drake R.R., et al. Surface Enhanced laser desorption ionization time of flight differentiation of serum protein profiles of BRCA 1 and sporadic breast cancer. Ann Surg Oncol 2004, 11(10):907-914.
19. Atahan K., Kupeli H., Gur S., Yigitbasi T., Baskin Y., Yigit S., et al. The value of serum biomarkers (Bc1, Bc2, Bc3) in the diagnosis of early breast cancer. Int J Med Sci 2011, 8(2):148-155.
20. Heckman-Stoddard B.M. Oncology Biomarkers: Discovery, Validation, and Clinical Use. Semin Nurs Oncol 2012, 93-98.
21. Tirumalai R.S., Chan K.C., Prieto D.A., Issaq H.J., Conrads T.P., Veenstra T.D., et al. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003, 2:1096-1103.
22. Aresta A., Calvano C.D., Palmisano F., Zambonin C.G., Monaco A., Tommasi S., et al. Impact of sample preparation in peptide/protein profiling in human serum by MALDI TOF mass spectrometry. J Pharm Biomed Anal 2008, 46(1):157-164.
23. Zahnow C.A. CCAAT/enhancer-binding protein β: its role in breast cancer and associations with receptor tyrosine kinases. Expert Rev Mol Med. 2009, 11(e12).